AQP4 and neuromyelitis optica: This problem is not unique to Indonesia, since multinational studies on availability and affordability of NMO diagnostic testing showed that AQP4-IgG testing facilities are only available in 38% of low-income countries, indicating a gap in access to diagnostic testing for NMO [26].